Co-Principal Investigator for OncoSec’s Phase II Merkel Cell Carcinoma Study to Speak at 70th Annual American Academy of Dermatology Meeting
SAN DIEGO, March 19, 2012 /PRNewswire/ — OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Dr. Paul Nghiem, Co-Principal Investigator for OncoSec’s Phase II Merkel cell carcinoma study has been invited to chair a special forum session at the 70th Annual American Academy of Dermatology meeting in San Diego, CA, titled, “Merkel Cell Carcinoma: Diagnosis, Management, and Controversies”. During this session, Dr. Nghiem will present on Prognostics, Immunity and Future Therapies for Merkel cell carcinoma.
Dr. Nghiem said, “MCC is an orphan disease that still has very few treatment options for the patient, however, recognition of this disease at this conference is an encouraging step forward. I look forward to chairing this session, and to discussing new findings and potential therapies for MCC, including OncoSec’s OMS ElectroImmunotherapy treatment approach, with experts in the field.”
70th Annual American Academy of Dermatology Meeting
San Diego Convention Center
111 West Harbor Drive
San Diego, CA
March 16-20, 2012
Merkel Cell Carcinoma: Diagnosis, Management, and Controversies
March 20, 2012
9:00 – 11:00am PT
About Merkel Cell Carcinoma
Merkel cell carcinoma is a rare and highly aggressive cancer, in which malignant cancer cells develop on, or just beneath, the skin and in hair follicles. Roughly 1,500 cases per year in the United States are diagnosed, making it about 40 times less common than melanoma. More significantly, it is three times more lethal, thus prompt aggressive treatment is warranted. The majority of Merkel cell carcinomas (~80%) appear to be caused in part by a virus, Merkel cell polyomavirus. It is believed that an immunotherapy, which stimulates the immune system to recognize and kill the virus and cancer may be a beneficial therapy for this patient population.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec’s core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated